Deciphering the oncogenic role of Rac family small GTPase 3 in hepatocellular carcinoma through multiomics integration

Figure 3 Clinical relevance of Rac family small GTPase 3 dysregulation in hepatocellular carcinoma. A: Representative immunohistochemical (IHC) staining demonstrating differential Rac family small GTPase 3 (RAC3) expression between hepatocellular carcinoma and adjacent non-tumorous liver tissues; B: Quantitative comparison of IHC H-scores in matched tumor-normal pairs (P < 0.001, paired t-test); C: Diagnostic performance evaluation using receiver operating characteristic curve analysis (area under curve = 0.82, 95%CI: 0.76–0.89); D: Kaplan–Meier survival curves stratified by RAC3 expression levels with clinicopathological correlations. AUC: Area under curve; HCC: Hepatocellular carcinoma; RAC3: Rac family small GTPase 3.